Cytoclonal Announces Production System for Gaucher's Disease.

Business/Medical & Technology Editors

DALLAS--(BUSINESS WIRE)--April 10, 2000

Cytoclonal Pharmaceutics Inc. (NASDAQ:CYPH, CYPHZ) announced today development of a proprietary production system for making the enzyme gluco-cerebrosidase which is defective in the genetic disorder Gaucher's disease.

Presently the enzyme is made by a costly process and sold by Genzyme as Ceredase(R) and Cerezyme(R). The worldwide market is about $500 million.

The goal of Cytoclonal's Gaucher program is to provide a more cost-effective source of the enzyme for the Gaucher patient. The genetic defect in this disease results in multi-organ disease including lung, liver and kidney disease and occurs in a high frequency in the Jewish population.

Cytoclonal is utilizing two leading advisors for its Gaucher program, which is under the direction of Dr. Susan Berent. Dr. Ari Zimran, who is located in Israel, is a leader in the treatment and clinical trials for Gaucher disease. Dr. Rob Shorr was involved in commercial development of several products for Enzon, Inc. Both experts are consultants and working closely with Cytoclonal for its Gaucher program.

The Company is in negotiations with a potential strategic partner for commercialization in Israel and Europe. There are approximately 20,000 patients worldwide, which could qualify the disease for orphan drug status.

"The Gaucher program is an extension of Cytoclonal's efforts to improve production of established drugs," said Dr. Arthur P. Bollon, Chairman and Chief Executive Officer of Cytoclonal. "Another major thrust in these efforts involves our fermentation and genetic engineering program for Taxol(R) with Bristol-Myers Squibb."

Cytoclonal Pharmaceutics is a biopharmaceutical company specializing in the development of therapeutic and diagnostic products for the treatment and prevention of cancer and other diseases. Based in Dallas, Texas, the Company's lead programs involve paclitaxel (active ingredient in Taxol(R)) production using fermentation and genetic engineering in agreements with Bristol-Myers Squibb, and the treatment of Polycystic Kidney Disease using paclitaxel. Other lead programs include Quantum Core Technology(TM), the Company's proprietary rational drug design, targeting proteins, and OASIS(TM) optimized antisense library for regulating genes. Other programs involve the discovery of human genes through Retroselection(TM) with a focus on lung cancer and breast cancer treatment by peptide inhibition of estrogen receptors. An additional program involves production and regulation of the "immortality enzyme" telomerase. Additional information on Cytoclonal can be found on the Company's website at www.cytoclonal.com.

Except for historical information, the matters discussed in this news release may be considered "forward looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.